logo

For the Inventor, By the Inventor

East Windsor, NJ, United States of America

Donald S Karanewsky

This inventor holds 61 USPTO granted patents, plus 1 CIPO patent, primarily in Cysteine Protease Inhibition (CPC class 514 ). Top assignees: E. R. Squibb Sons, Inc., Idun Pharmaceuticals, Inc., Bristol-Myers Squibb Compnay. Active years: 1983-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Donald S Karanewsky. Retrieved from https://idiyas.com/inventor/donald-s-karanewsky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 61

% Patents Active = 100.0

 

Average Co-Inventor Count = 1.7

ph-index = 20

Forward Citations = 873(Granted Patents)

Forward Citations (Not Self Cited) = 814(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Princeton Junction, NJ (US) (1983 - 1987)
  • Robbinsville, NJ (US) (1991 - 1993)
  • East Windsor, NJ (US) (1984 - 1994)
  • West Windsor, NJ (US) (1992 - 1995)
  • Chapel Hill, NC (US) (1996 - 1998)
  • Escondido, CA (US) (1997 - 2001)

Company Filing History:

goldMedal50 out of 1,624 
 
E. R. Squibb Sons, Inc.
 patents
silverMedal7 out of 33 
 
Idun Pharmaceuticals, Inc.
 patents
bronzeMedal1 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
4. 1 out of 1 
 
Idun Pharmacueticals, Inc.
 patent
5. 2 out of 834,601 
Other
 patents

Years Active: 1983-2001

Loading Chart...
Loading Chart...
Areas of Expertise:
Cysteine Proteases
NADPH Oxidase
HMG-CoA Reductase
Angiotensin Converting Enzyme
Antihypertensives
Dipeptides
Tricyclic Compounds
Phosphonyl Hydroxyacyl
Amino Acid Derivatives
Thiazine Compounds
Hydroxamates
Dual Action Inhibitors
61 patents (USPTO):Explore Patents
1. 6242422 - (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases (2001-06-05),
2. 6197750 - C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2001-03-06),
3. 6187771 - Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes (2001-02-13),
4. 6184244 - C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases (2001-02-06),
5. 5990137 - Method of inhibiting NADPH oxidase (1999-11-23),
6. 5968927 - Tricyclic compounds for the inhibition of the ICE/ced-3 protease family (1999-10-19),
7. 5939460 - Method of inhibiting NADPH oxidase (1999-08-17),
8. 5877197 - C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors (1999-03-02),
9. 5869519 - C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors (1999-02-09),
10. 5859239 - Mercaptoalkanoylamino and acylmercaptoalkanoylamino benzoxazepines and (1999-01-12),
11. 5723602 - Dual action inhibitors containing a pyridazinodiazepine or (1998-03-03),
12. 5723457 - Acylmercaptoalkanoylamino and mercaptoalkanoylamino benzazepines (1998-03-03),
13. 5650408 - Thiazolo benzazepine containing dual action inhibitors (1997-07-22),
14. 5552397 - Substituted azepinone dual inhibitors of angiotensin converting enzyme (1996-09-03),
15. 5504080 - Benzo-fused lactams (1996-04-02),

Title: The Innovative Contributions of Donald S. Karanewsky

Introduction: Donald S. Karanewsky, a prominent inventor based in East Windsor, NJ, is renowned for his significant contributions to the field of pharmaceutical innovations. With an impressive portfolio of 61 patents, Karanewsky has dedicated his career to developing novel compounds aimed at treating various diseases.

Latest Patents: Among his latest inventions are two groundbreaking patents. The first patent, titled "Substituted Acyl Dipeptidyl Inhibitors of the Ice/Ced-3 Family of Cysteine Proteases," focuses on innovative (substituted) acyl dipeptidyl inhibitors. This invention not only highlights new compounds but also emphasizes pharmaceutical compositions intended for treating inflammatory, autoimmune, and neurodegenerative diseases, as well as preventing ischemic injuries and preserving organs for transplantation.

The second patent, "C-terminal Modified Oxamyl Dipeptides as Inhibitors of the ICE/Ced-3 Family of Cysteine Proteases," introduces novel oxamyl dipeptide inhibitors. Similar to his first patent, this invention also revolves around the development of pharmaceutical compositions for treating various disease conditions and for organ preservation during transplants.

Career Highlights: Karanewsky's career is marked by his association with well-known companies, such as E.R. Squibb & Sons, Inc. and Idun Pharmaceuticals, Inc. At these organizations, he contributed to advancements in pharmaceutical research and development, elevating the standards of medical treatments available today.

Collaborations: Throughout his career, Karanewsky has collaborated with distinguished professionals, including Edward W. Petrillo, Jr. and Eric M. Gordon. These collaborations have played a vital role in his research endeavors, fostering an environment of innovation and shared expertise.

Conclusion: Donald S. Karanewsky's inventive spirit and dedication to pharmaceutical science have led to numerous patents that greatly impact the medical field. His work continues to inspire future innovations and improvements in treatment methodologies, positioning him as a valuable contributor to the world of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…